Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 15, 2026Notice of sale · Form 144PABLO CAGNONI · Officer · $297.8KOpen the filing ↗
- Sep 15, 2026Reported sale · Form 4PABLO J CAGNONI, President, Global Head of R&D · $1.1MOpen the filing ↗
- Sep 15, 2026Reported sale · Form 4PABLO J CAGNONI, President, Global Head of R&D · $1.7MOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,3838 flagged findings
Reported transactions (Form 4)80since Jul 16, 2026 · and 17 other holdings
Corporate events (8-K)30since Sep 6, 2018
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-04-28capital return (buybacks/dividends)recentOpen filing ↗“…in cash, cash equivalents, and restricted cash 363,281 253,936 Cash, cash equivalents, and restricted cash at beginning of period…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 2,383)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 15, 26Form 144 ↗Notice of proposed sale new
- Sep 15, 26Form 144 ↗Notice of proposed sale
- Aug 31, 268-K ↗Current report · Other events
- Aug 19, 26Form 144 ↗Notice of proposed sale
- Aug 14, 26Form 4 ↗Insider transaction
- Aug 12, 26Form 144 ↗Notice of proposed sale
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Aug 5, 26Form 144 ↗Notice of proposed sale
- Aug 5, 26Form 144 ↗Notice of proposed sale
Notice of proposed sale · 3 Form 144 filingsshow all 3hide
- Aug 3, 26Form 144 ↗Notice of proposed sale
- Jul 31, 26Form 144 ↗Notice of proposed sale
- Jul 31, 26Form 144 ↗Notice of proposed sale
- Jul 28, 2610-Q ↗Quarterly report
- Jul 28, 268-K ↗Current report · Results
2,383 filings on record, the oldest from Feb 11, 94.
Listing the 25 most recent filings of the 2,383 on record.
4665
8 senior executive changes2025 – 2026show all 8hide
- Mar 30, 26A senior executive left or was appointed8-K 5.02 ↗
- Mar 26, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 12, 25A senior executive left or was appointed8-K 5.02 ↗
- Oct 3, 25A senior executive left or was appointed8-K 5.02 ↗
- Aug 7, 25A senior executive left or was appointed8-K 5.02 ↗
- Jun 27, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 11, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 10, 25A senior executive left or was appointed8-K 5.02 ↗
- Jul 3, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- May 13, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 senior executive changes2021 – 2023show all 6hide
- Sep 12, 23A senior executive left or was appointed8-K 5.02 ↗
- Jun 15, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Oct 4, 22A senior executive left or was appointed8-K 5.02 ↗
- Apr 21, 22A senior executive left or was appointed8-K 5.02 ↗
- Jan 14, 22A senior executive left or was appointed8-K 5.02 ↗
- Sep 28, 21A senior executive left or was appointed8-K 5.02 ↗
- Aug 20, 21Took on a new financial obligation+1 more in the same filing8-K 2.03 ↗
5 senior executive changes2020 – 2021show all 5hide
- May 27, 21A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 27, 20A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 14, 20A senior executive left or was appointed8-K 5.02 ↗
- Apr 20, 20A senior executive left or was appointed8-K 5.02 ↗
- Mar 26, 20A senior executive left or was appointed8-K 5.02 ↗
- Jan 16, 20Entered a material agreement+2 more in the same filing8-K 1.01 ↗
5 senior executive changes2018 – 2019show all 5hide
- Dec 19, 19A senior executive left or was appointed8-K 5.02 ↗
- Apr 30, 19A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 3, 19A senior executive left or was appointed8-K 5.02 ↗
- Nov 27, 18A senior executive left or was appointed8-K 5.02 ↗
- Sep 6, 18A senior executive left or was appointed8-K 5.02 ↗
The record reaches back to Mar 30, 05.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Julian C. Baker15.6%May 7, 26SCHEDULE 13D/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.7.8%Sep 30, 25SCHEDULE 13G/A ↗
- Vanguard Capital Management6.3%Mar 31, 26SCHEDULE 13G ↗
- Dodge & Cox6.2%Mar 31, 26SCHEDULE 13G/A ↗
- STATE STREET CORPORATION5.0%Sep 30, 25SCHEDULE 13G ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 15, PABLO CAGNONI filed notice of intent to sell up to $298K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
No sale of theirs is on record yet in Form 4; the 90-day window is still open.
View notice (Form 144) ↗+9 more recent notices · 9 with a later sale
- Sep 15, 26Sell$1.1MPABLO J CAGNONIPresident, Global Head of R&D↗
- Sep 15, 26Sell$1.7MPABLO J CAGNONIPresident, Global Head of R&D↗
- Aug 19, 26Sell$1.4MPABLO J CAGNONIPresident, Global Head of R&D↗
- Aug 12, 26Sell$1.3MPABLO J CAGNONIPresident, Global Head of R&D↗
- Aug 5, 26Sell$1.3MPABLO J CAGNONIPresident, Global Head of R&D↗
- Aug 5, 26Sell$274KPatrick A MayesEVP & Chief Scientific Officer↗
- Aug 3, 26Sell$729KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Sell$1.9MPABLO J CAGNONIPresident, Global Head of R&D↗
- Jul 31, 26Sell$1.8MPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Sell$637KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Sell$261KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Sell$737KPatrick A MayesEVP & Chief Scientific Officer↗
Stock compensation, tax and giftsshow the 28 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 1, 26Tax$54KLee HeesonEVP, Head of Incyte Intl↗
- Sep 30, 26Compensation$25KEDMUND HARRIGAN↗
- Sep 30, 26Compensationamount n/aBAKER BROS. ADVISORS LP↗
- Sep 30, 26Compensationamount n/aBAKER BROS. ADVISORS LP↗
- Sep 30, 26Compensation$25KPaul J Clancy↗
- Sep 22, 26Tax$117KDavid H GardnerEVP, Chief Strategy Officer↗
- Sep 15, 26Compensation$183KPABLO J CAGNONIPresident, Global Head of R&D↗
- Sep 15, 26Compensation$278KPABLO J CAGNONIPresident, Global Head of R&D↗
- Sep 15, 26Compensation$416KPABLO J CAGNONIPresident, Global Head of R&D↗
- Sep 15, 26Compensation$664KPABLO J CAGNONIPresident, Global Head of R&D↗
- Aug 25, 26Tax$65KRamitpal K BasiEVP, Human Resources↗
- Aug 5, 26Compensation$235KPatrick A MayesEVP & Chief Scientific Officer↗
- Aug 3, 26Compensation$638KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$179KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$147KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$167KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$216KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$149KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$684KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$196KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$222KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$132KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$252KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$219KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$140KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$208KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$9KPatrick A MayesEVP & Chief Scientific Officer↗
- Jul 31, 26Compensation$34KPatrick A MayesEVP & Chief Scientific Officer↗
The full record holds 473 transactions and goes back to Dec 30, 22.
Its sector and its market
Incyte Corporation among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Incyte Corporation, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Incyte Corporation in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,383 documents on file, from Feb 11, 1994 to Oct 15, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.